1-3 of 3
Jeffrey I. Weitz, MDFRCPC
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Christina U Lorentz, PhD, Norah G Verbout, PhD, Joseph J Shatzel, MD, Michael Wallisch, PhD, Brandon D Markway, PhD, Monica T Hinds, PhD, Owen J T McCarty, PhD, David Gailani, MD, Jeffrey I. Weitz, MDFRCPC, Erik I Tucker, PhD, András Gruber, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-139948
Published: 2020
Journal Articles

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

Harry Roger Buller, MD PhD, Claudette Bethune, PhD, Sanjay Bhanot, MDPhD, David Gailani, MD, Brett P. Monia, PhD, Gary E. Raskob, PhD, Annelise Segers, Peter Verhamme, MD PhD, Jeffrey I. Weitz, MDFRCPC
Journal: Blood
Blood (2014) 124 (21): LBA-1.
https://doi.org/10.1182/blood.V124.21.LBA-1.LBA-1
Published: 2014
Journal Articles

Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data

Alexander Cohen, MD, Alexander S. Gallus, MD, Giancarlo Agnelli, MD, Harry R Buller, MD PhD, Raphael Pak, PhD, Anthony R. Porcari, PhD PharmD, Gary E. Raskob, PhD, Jeffrey I. Weitz, MDFRCPC, Takaharu Yamabe, PhD
Journal: Blood
Blood (2014) 124 (21): 1543.
https://doi.org/10.1182/blood.V124.21.1543.1543
Published: 2014